BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17938809)

  • 1. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
    Frere C; Cuisset T; Quilici J; Camoin L; Carvajal J; Morange PE; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Thromb Haemost; 2007 Oct; 98(4):838-43. PubMed ID: 17938809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
    Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
    Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.
    Cuisset T; Frere C; Quilici J; Morange PE; Camoin L; Bali L; Lambert M; Juhan-Vague I; Alessi MC; Bonnet JL
    Thromb Res; 2009 Feb; 123(4):597-603. PubMed ID: 18499233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
    Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
    Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
    J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
    Cuisset T; Hamilos M; Delrue M; Frère C; Verhamme K; Bartunek J; Saut N; Bonnet JL; Eijgelsheim M; Wijns W; Alessi MC; Barbato E
    Thromb Haemost; 2010 Apr; 103(4):774-9. PubMed ID: 20135061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
    JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
    Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
    Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
    Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.
    Frere C; Cuisset T; Morange PE; Quilici J; Camoin-Jau L; Saut N; Faille D; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Am J Cardiol; 2008 Apr; 101(8):1088-93. PubMed ID: 18394438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
    Bidet A; Jais C; Puymirat E; Coste P; Nurden A; Jakubowski J; Nurden P
    Platelets; 2010; 21(2):94-100. PubMed ID: 20148735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
    Siller-Matula JM; Lang I; Christ G; Jilma B
    J Am Coll Cardiol; 2008 Nov; 52(19):1557-63. PubMed ID: 19007592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?
    Cotton JM; Worrall AM; Hobson AR; Smallwood A; Amoah V; Dunmore S; Nevill AM; Raghuraman RP; Vickers J; Curzen N
    Cardiovasc Ther; 2010 Jun; 28(3):139-46. PubMed ID: 20406238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
    Kobsar AL; Koessler J; Rajkovic MS; Brunner KP; Steigerwald U; Walter U
    Platelets; 2010; 21(2):112-6. PubMed ID: 20085435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.